JP7800865B2 - ジヒドロオロト酸デヒドロゲナーゼの阻害のための方法および組成物 - Google Patents

ジヒドロオロト酸デヒドロゲナーゼの阻害のための方法および組成物

Info

Publication number
JP7800865B2
JP7800865B2 JP2022538733A JP2022538733A JP7800865B2 JP 7800865 B2 JP7800865 B2 JP 7800865B2 JP 2022538733 A JP2022538733 A JP 2022538733A JP 2022538733 A JP2022538733 A JP 2022538733A JP 7800865 B2 JP7800865 B2 JP 7800865B2
Authority
JP
Japan
Prior art keywords
hydrogen
compound according
alkyl
compound
disclosed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022538733A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023512413A5 (https=
JP2023512413A (ja
Inventor
シー． バード，ジョン
イー． ベネット，チャド
マドフカ ヴィブート，サンディップ
イー． グッドウィン，トーマス
ハートライン，エリン
エイ． エルガマル，オラ
アロン ウィルソン，テイラー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hendrix College
Original Assignee
Hendrix College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hendrix College filed Critical Hendrix College
Publication of JP2023512413A publication Critical patent/JP2023512413A/ja
Publication of JP2023512413A5 publication Critical patent/JP2023512413A5/ja
Application granted granted Critical
Publication of JP7800865B2 publication Critical patent/JP7800865B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C07D215/52—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2022538733A 2019-12-26 2020-12-26 ジヒドロオロト酸デヒドロゲナーゼの阻害のための方法および組成物 Active JP7800865B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962953708P 2019-12-26 2019-12-26
US62/953,708 2019-12-26
PCT/US2020/067065 WO2021134042A1 (en) 2019-12-26 2020-12-26 Methods and compositions for inhibition of dihydroorotate dehydrogenase

Publications (3)

Publication Number Publication Date
JP2023512413A JP2023512413A (ja) 2023-03-27
JP2023512413A5 JP2023512413A5 (https=) 2024-01-25
JP7800865B2 true JP7800865B2 (ja) 2026-01-16

Family

ID=76575157

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022538733A Active JP7800865B2 (ja) 2019-12-26 2020-12-26 ジヒドロオロト酸デヒドロゲナーゼの阻害のための方法および組成物

Country Status (6)

Country Link
US (1) US20240018108A1 (https=)
EP (1) EP4081215A4 (https=)
JP (1) JP7800865B2 (https=)
AU (1) AU2020411507A1 (https=)
CA (1) CA3165512A1 (https=)
WO (1) WO2021134042A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020412805A1 (en) * 2019-12-26 2022-07-14 Hendrix College Methods and compositions for inhibition of dihydroorotate dehydrogenase in combination with an anti-CD38 therapeutic agent

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110263620A1 (en) 2010-04-23 2011-10-27 National Health Research Institutes Quinoline compounds and their use for treating viral infection
WO2019246603A1 (en) 2018-06-22 2019-12-26 Ohio State Innovation Foundation Methods and compositions for inhibition of dihydroorotate dehydrogenase

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4680299A (en) * 1984-04-30 1987-07-14 E.I. Du Pont De Nemours And Company 2-phenyl-4-quinolinecarboxylic acids and pharmaceutical compositions thereof
AU2020412805A1 (en) * 2019-12-26 2022-07-14 Hendrix College Methods and compositions for inhibition of dihydroorotate dehydrogenase in combination with an anti-CD38 therapeutic agent

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110263620A1 (en) 2010-04-23 2011-10-27 National Health Research Institutes Quinoline compounds and their use for treating viral infection
WO2019246603A1 (en) 2018-06-22 2019-12-26 Ohio State Innovation Foundation Methods and compositions for inhibition of dihydroorotate dehydrogenase

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Joseph T. Madak et al.，Design, Synthesis, and Biological Evaluation of 4-Quinoline Carboxylic Acids as Inhibitors of Dihydroorotate Dehydrogenase，J.Med.Chem.，2018年，Vol.61, No.12，pp.5162-5186

Also Published As

Publication number Publication date
JP2023512413A (ja) 2023-03-27
AU2020411507A1 (en) 2022-07-14
EP4081215A1 (en) 2022-11-02
CA3165512A1 (en) 2021-07-01
KR20220132538A (ko) 2022-09-30
WO2021134042A1 (en) 2021-07-01
US20240018108A1 (en) 2024-01-18
EP4081215A4 (en) 2024-01-10
CN115361948A (zh) 2022-11-18

Similar Documents

Publication Publication Date Title
JP7373170B2 (ja) ジヒドロオロト酸デヒドロゲナーゼ阻害のための方法及び組成物
CA3161373A1 (en) Compositions and methods for substituted 7-(piperazin-1-yl)pyrazolo[1,5-a]pyrimidine analogs as inhibitors of kras
KR102765922B1 (ko) 선택적인 에스트로겐 수용체 분해제로서의 치환된 벤조티오펜 유사체
JP7736275B2 (ja) 抗ｃｄ３８治療剤と組み合わせたジヒドロオロト酸デヒドロゲナーゼの阻害のための方法および組成物
JP7800865B2 (ja) ジヒドロオロト酸デヒドロゲナーゼの阻害のための方法および組成物
US20230089524A1 (en) Compositions for use in the inhibition of dihydroorotate dehydrogenase
US20230109418A1 (en) Compositions for use for the inhibition of dihydroorotate dehydrogenase
CN115361948B (en) Methods and compositions for inhibiting dihydroorotate dehydrogenase
KR102956115B1 (ko) 디하이드로오로테이트 데하이드로게나제를 억제하는 방법 및 조성물
WO2023096995A1 (en) Compositions and methods comprising substituted n-(2-chloro-6-methylphenyl)-2-((6-(6-membered heterocycloalkyl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide analogues
HK40084674A (en) Methods and compositions for inhibition of dihydroorotate dehydrogenase
WO2025227007A1 (en) Methods and compositions for inhibition of dihydroorotate dehydrogenase
HK40043086B (en) Methods and compositions for inhibition of dihydroorotate dehydrogenase
HK40043086A (en) Methods and compositions for inhibition of dihydroorotate dehydrogenase

Legal Events

Date Code Title Description
A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20220815

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231226

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240117

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250430

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250731

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250930

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251125

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251219

R150 Certificate of patent or registration of utility model

Ref document number: 7800865

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150